Cartesian Therapeutics Inc. Total Assets
Cartesian Therapeutics Inc. total assets. Based on the latest financial reports, Cartesian Therapeutics Inc. (RNAC) holds total assets worth $288.39 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see RNAC stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Cartesian Therapeutics Inc. (2014–2025)
Total assets of Cartesian Therapeutics Inc. from 2014 to 2025. This chart illustrates how Cartesian Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Cartesian Therapeutics Inc. for real-time trading data and today's change.
Cartesian Therapeutics Inc. - Asset Composition Analysis
Cartesian Therapeutics Inc. Total Assets Breakdown (December 2025)
Cartesian Therapeutics Inc. total assets breakdown as of December 2025. Cartesian Therapeutics Inc.'s total assets of $288.39 Million consist of 43.6% current assets and 56.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.2% |
| Accounts Receivable | $1.11 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $93.90 Million | 31.7% |
| Goodwill | $48.16 Million | 16.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how Cartesian Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Cartesian Therapeutics Inc. (RNAC) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cartesian Therapeutics Inc.'s current assets represent 43.6% of total assets in 2025, a decrease from 86.0% in 2014.
- Cash Position: Cash and equivalents constituted 42.2% of total assets in 2025, down from 74.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 31.7% of total assets.
Cartesian Therapeutics Inc. Competitors by Total Assets
Key competitors of Cartesian Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Cartesian Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.65 | 12.34 | 1.91 |
| Quick Ratio | 7.65 | 12.34 | 1.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $106.09 Million | $170.12 Million | $79.52 Million |
Cartesian Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Cartesian Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 31.26 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | -31.9% |
| Total Assets | $296.41 Million |
| Market Capitalization | $172.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cartesian Therapeutics Inc.'s assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cartesian Therapeutics Inc.'s assets decreased by 31.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cartesian Therapeutics Inc. (2014–2025)
The table below shows the annual total assets of Cartesian Therapeutics Inc. from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $296.41 Million | -31.86% |
| 2024-12-31 | $435.02 Million | +42.61% |
| 2023-12-31 | $305.05 Million | +83.89% |
| 2022-12-31 | $165.89 Million | +3.75% |
| 2021-12-31 | $159.88 Million | -3.36% |
| 2020-12-31 | $165.44 Million | +66.15% |
| 2019-12-31 | $99.57 Million | +123.84% |
| 2018-12-31 | $44.48 Million | -56.00% |
| 2017-12-31 | $101.10 Million | +13.21% |
| 2016-12-31 | $89.30 Million | +108.53% |
| 2015-12-31 | $42.82 Million | +92.66% |
| 2014-12-31 | $22.23 Million | -- |
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more